C4 Therapeutics (CCCC) Enterprise Value (2019 - 2025)
Historic Enterprise Value for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$191.9 million.
- C4 Therapeutics' Enterprise Value rose 2494.01% to -$191.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 2494.01%. This contributed to the annual value of -$244.9 million for FY2024, which is 345.99% up from last year.
- Per C4 Therapeutics' latest filing, its Enterprise Value stood at -$191.9 million for Q3 2025, which was up 2494.01% from -$214.6 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Enterprise Value registered a high of -$191.9 million during Q3 2025, and its lowest value of -$465.9 million during Q2 2021.
- Over the past 5 years, C4 Therapeutics' median Enterprise Value value was -$267.3 million (recorded in 2023), while the average stood at -$280.6 million.
- Over the last 5 years, C4 Therapeutics' Enterprise Value had its largest YoY gain of 4477.18% in 2021, and its largest YoY loss of 33279.36% in 2021.
- Quarter analysis of 5 years shows C4 Therapeutics' Enterprise Value stood at -$309.3 million in 2021, then increased by 10.71% to -$276.2 million in 2022, then rose by 8.14% to -$253.7 million in 2023, then increased by 3.46% to -$244.9 million in 2024, then increased by 21.65% to -$191.9 million in 2025.
- Its Enterprise Value stands at -$191.9 million for Q3 2025, versus -$214.6 million for Q2 2025 and -$215.1 million for Q1 2025.